1. Academic Validation
  2. Targeting SARS-CoV-2 and host cell receptor interactions

Targeting SARS-CoV-2 and host cell receptor interactions

  • Antiviral Res. 2023 Feb:210:105514. doi: 10.1016/j.antiviral.2022.105514.
Siew Pheng Lim 1
Affiliations

Affiliation

  • 1 Experimental Drug Development Centre (EDDC), A*STAR, 10, Biopolis Road, #05-01, Chromos, 138670, Singapore. Electronic address: [email protected].
Abstract

Despite the availability of vaccines and therapeutics, continual genetic alterations render the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) a persistent threat, particularly for the immunocompromised and elderly. Through interactions of its spike (S) protein with different receptors and coreceptors on host cell surfaces, the virus enters the cell either via fusion with the plasma membrane or through endocytosis. Angiotensin-converting Enzyme 2 (ACE2) has been identified as a key receptor utilized by SARS-CoV-2 and related human coronaviruses to mediate cell entry in the lung airways. Auxiliary SARS-CoV-2 entry receptors such as ASGPR1, Kremen protein 1, integrins have also been reported. In this review, therapeutic approaches to block SARS-CoV-2 and host cell receptor interactions are discussed.

Keywords

ACE2; Entry inhibitors; RBD; SARS-CoV-2; Screening; Spike.

Figures
Products